AURKA and leiomyosarcoma: For example, in this study 72% of patients were female, no patients with liposarcoma were enrolled (known activity to AURKA inhibitors)15, and almost half of the patients had leiomyosarcoma histology (compared to 30% in the PALETTE4 study) which may have influenced outcomes.